TFF Pharmaceuticals (NASDAQ:TFFP – Get Free Report) and NeuroSense Therapeutics (NASDAQ:NRSN – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.
Risk & Volatility
TFF Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.
Insider and Institutional Ownership
15.3% of TFF Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 4.5% of TFF Pharmaceuticals shares are owned by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TFF Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| NeuroSense Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
Profitability
This table compares TFF Pharmaceuticals and NeuroSense Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TFF Pharmaceuticals | -1,596.64% | -310.17% | -196.06% |
| NeuroSense Therapeutics | N/A | N/A | -590.79% |
Earnings and Valuation
This table compares TFF Pharmaceuticals and NeuroSense Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TFF Pharmaceuticals | -$70,983.00 | -4.07 | -$21.24 million | ($6.44) | -0.01 |
| NeuroSense Therapeutics | N/A | N/A | -$11.28 million | ($0.54) | -1.85 |
NeuroSense Therapeutics has higher revenue and earnings than TFF Pharmaceuticals. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than TFF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroSense Therapeutics beats TFF Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
